Dashboard
Manage Tickers

IKTInhibikase Therapeutics, Inc.

Nasdaq inhibikase.com


$ 1.54 $ -0.05 (-3.14 %)    

Tuesday, 30-Apr-2024 09:41:21 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 428.15 $ -4.03 (-0.93 %)
DIA $ 379.91 $ -4.15 (-1.08 %)
SPY $ 505.46 $ -2.45 (-0.48 %)
TLT $ 88.48 $ 0.01 (0.01 %)
GLD $ 212.52 $ -1.43 (-0.67 %)
$ 1.59
$ 1.54
$ 0.00 x 0
$ 0.00 x 0
$ 1.54 - $ 1.54
$ 0.79 - $ 4.35
40,442
na
8.48M
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-27-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-vaxxinity-shares-are-trading-lower-by-around-55-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Vaxxinity Shares Are Trading Lower By ...
04/22/2024 17:26:48

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
04/22/2024 16:31:48

inhibikase-therapeutics-issues-letter-to-shareholders-and-provides-update-on-development-programs-says-201-trial-is-75-enrolled
Inhibikase Therapeutics Issues Letter To S...
04/18/2024 20:37:32

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein ...

inhibikase-therapeutics-announces-apr-5-pre-ind-meeting-with-fda-for-ikt-001pro-in-pulmonary-arterial-hypertension
Inhibikase Therapeutics Announces Apr. 5 P...
04/03/2024 12:07:57

inhibikase-therapeutics-q4-eps-064-beats-085-estimate-sales-100k-down-from-6357k-yoy
Inhibikase Therapeutics Q4 EPS $(0.64) Bea...
03/28/2024 03:45:50

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate o...

inhibikase-therapeutics-fy23-eps-357-cash-position-133m-as-of-dec-31
Inhibikase Therapeutics FY23 EPS $(3.57); ...
03/27/2024 20:38:40

hc-wainwright--co-reiterates-buy-on-inhibikase-therapeutics-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Inhi...
03/07/2024 16:26:19

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 pr...

inhibikase-therapeutics-to-provide-trial-update-for-risvodetinib-at-the-2024-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders
Inhibikase Therapeutics To Provide Trial U...
03/07/2024 13:37:27

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

hc-wainwright--co-maintains-buy-rating-for-inhibikase-therapeutics-heres-what-you-need-to-know
HC Wainwright & Co. Maintains Buy Rating f...
03/05/2024 17:00:30

hc-wainwright--co-maintains-buy-on-inhibikase-therapeutics-maintains-27-price-target
HC Wainwright & Co. Maintains Buy on Inhib...
03/05/2024 15:50:51

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 pri...

inhibikase-therapeutics-announces-full-outcomes-of-its-pre-nda-meeting-with-the-fda-for-ikt-001pro
Inhibikase Therapeutics Announces Full Out...
02/28/2024 21:51:57

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

inhibikase-reports-preliminary-outcomes-of-pre-nda-meeting-with-fda-on-pathway-for-approval-for-ikt-001pro-in-blood-and-gastrointestinal-cancers-says-given-specific-guidance-on-manufacturing-requirements-necessary-to-complete-nda
Inhibikase Reports Preliminary Outcomes Of...
02/07/2024 12:57:50

inhibikase-therapeutics-announces-publication-highlighting-results-from-its-phase-1-studies-with-risvodetinib
Inhibikase Therapeutics Announces Publicat...
01/29/2024 14:06:34

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
01/26/2024 17:31:09

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
01/25/2024 17:31:07

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
01/24/2024 17:31:02

inhibikase-therapeutics-appoints-garth-lees-rolfe-as-cfo-succeeds-joseph-frattaroli
Inhibikase Therapeutics Appoints Garth Lee...
01/16/2024 21:12:04

why-dermata-therapeutics-shares-are-trading-higher-by-over-57-here-are-20-stocks-moving-premarket
Why Dermata Therapeutics Shares Are Tradin...
01/05/2024 13:03:11

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuan...

inhibikase-therapeutics-issues-letter-to-shareholders-and-provides-update-on-development-programs
Inhibikase Therapeutics Issues Letter To S...
12/19/2023 13:41:52

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein ...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
12/13/2023 13:07:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION